Prognostic analysis of adjuvant chemotherapy in patients with nasopharyngeal carcinoma

Future Oncology

Volumn 9, Issue 10, 2013, Pages 1469-1476

  Lin, Ching Chan ^a,b   Chen, Tzu Ting ^a   Lin, Chen Yuan ^a,b   Hsieh, Ching Yun ^a,b   Lin, Po Han ^a,b   Chien, Chun Ru ^a   Chiu, Chang Fang ^a,b,c   Yeh, Su Peng ^a,b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

adjuvant chemotherapy; cisplatin; fluorouracil; nasopharyngeal carcinoma; prognosis

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885600306     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.100     Document Type: Article

References (16)

1. Lee AW, Tung SY, Ngan RK et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 trials. Eur. J. Cancer 47(5), 656-666 (2011). Supports the use of adjuvant chemotherapy and noted that the dose of chemotherapy is important in disease control.
2. Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J. Clin. Oncol. 16(4), 1310-1317 (1998 (Pubitemid 28175745)
3. O'Sullivan B. Nasopharynx cancer: therapeutic value of chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 69(Suppl. 2), S118-S121 (2007 (Pubitemid 47369392)
4. Lee AW, Lau WH, Tung SY et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J. Clin. Oncol. 23(28), 6966-6975 (2005
5. Lee AW, Tung SY, Chua DT et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J. Natl Cancer Inst. 102(15), 1188-1198 (2010
6. Lee AW, Tung SY, Chan AT et al. Preliminary results of a randomized study (NPC-9902 trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 66(1), 142-151 (2006 (Pubitemid 44175659)
7. Wee J, Tan EH, Tai BC et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J. Clin. Oncol. 23(27), 6730-6738 (2005 (Pubitemid 46190268)
8. Chen Y, Liu MZ, Liang SB et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int. J. Radiat. Oncol. Biol. Phys. 71(5), 1356-1364 (2008
9. Baujat B, Audry H, Bourhis J et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int. J. Radiat. Oncol. Biol. Phys. 64(1), 47-56 (2006 (Pubitemid 41831208)
10. Loong HH, Ma BB, Leung SF et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother. Oncol. 104(3), 300-304 (2012
11. Chen L, Hu CS, Chen XZ et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a Phase 3 multicentre randomised controlled trial. Lancet Oncol. 13(2), 163-171 (2012). First prospective, randomized, controlled trial comparing head-to-head concurrent chemoradiation with and without adjuvant chemotherapy.
12. Lin JC, Liang WM, Jan JS, Jiang RS, Lin AC. Another way to estimate outcome of advanced nasopharyngeal carcinoma - is concurrent chemoradiotherapy adequate? Int. J. Radiat. Oncol. Biol. Phys. 60(1), 156-164 (2004 (Pubitemid 39165480)
13. Chua DT, Ma J, Sham JS et al. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: subgroup analysis of two Phase III trials. Int. J. Radiat. Oncol. Biol. Phys. 65(5), 1300-1306 (2006 (Pubitemid 44425202)
14. Lee NY, Zhang Q, Pfister DG et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a Phase 2 multi-institutional trial. Lancet Oncol. 13(2), 172-180 (2012
15. Hui EP, Ma BB, Leung SF et al. Randomized Phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J. Clin. Oncol. 27(2), 242-249 (2009
16. Kong L, Zhang YW, Hu CS, Guo Y. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma. Chin. J. Cancer 29(5), 551-555 (2010).